Transplant immunology最新文献

{"title":"The clinical significance of CD45RA+FOXP3low naïve and CD45RA−FOXP3high effector/memory Treg subsets in the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","authors":"Mani Ramzi ,&nbsp;Mohammadnabi Sanaei ,&nbsp;Maryam Hesamadini ,&nbsp;Hossein Golmoghaddam ,&nbsp;Mehdi Kalani ,&nbsp;Nargess Arandi","doi":"10.1016/j.trim.2025.102272","DOIUrl":"10.1016/j.trim.2025.102272","url":null,"abstract":"<div><h3>Introduction</h3><div>It has been proposed that regulatory T cells (Tregs) might be involved in the induction of transplantation tolerance after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, little is known about the role of Treg subsets in allo-HSCT outcomes, including the development of acute graft-versus-host disease (aGVHD). Herein, we assessed for the first time the association between the frequency of regulatory T cell (Treg) subsets, including CD45RA⁺FOXP3^low naïve (nTregs) and CD45RA⁻FOXP3^high effector/memory Tregs (eTregs), and aGVHD occurrence during 90 days after allo-HSCT.</div></div><div><h3>Methods</h3><div>Twenty-four pairs of donors/recipients with hematologic malignancies who underwent HLA-matched allo-HSCT were enrolled. The frequencies of nTregs and eTregs were determined via four-color flow cytometry.</div></div><div><h3>Results</h3><div>Compared with non-aGVHD patients, aGVHD patients had a lower frequency of nTregs in their donors (*<em>P</em> = 0.016). The reconstitution rate of nTregs was significantly slower on day +60 post-allo-HSCT in aGVHD patients than in non-aGVHD patients (*<em>P</em> = 0.025).</div><div>Patients who received grafts with nTregs&lt;0.19 and a median frequency of nTregs&lt;0.13 and eTregs&lt;0.58 on day +30 after transplantation presented a relatively high cumulative incidence of aGVHD (*<em>P</em> = 0.039, *<em>P</em> = 0.032, and *<em>P</em> = 0.036, respectively). Multivariate analysis revealed that a low median total number of Tregs recovered on days +30 and + 60 post-allo-HSCT was associated with an increased incidence of aGVHD [HR = 0.199, 95 % CI, 0.041–0.969; *<em>P</em> = 0.046 and HR = 0.092, 95 % CI, 0.011–0.765; *<em>P</em> = 0.026, respectively].</div></div><div><h3>Conclusion</h3><div>This study provides novel insights showing that high donor nTreg content and rapid recovery of nTregs and eTregs early on day 30 post-transplantation are closely linked to protection from aGVHD.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102272"},"PeriodicalIF":1.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of high-dose versus standard-dose influenza vaccines in hematopoietic stem cell transplant recipients: A meta-analysis of randomized controlled trials","authors":"Ananda Pipphali Vidya ,&nbsp;Nicholas Jason Wijaya ,&nbsp;Dhabitah Zahraa Puteri Gathmir ,&nbsp;Naira Ayesha Kayla Kornel ,&nbsp;Muhammad Farhan ,&nbsp;Imelda Rosalyn Sianipar","doi":"10.1016/j.trim.2025.102270","DOIUrl":"10.1016/j.trim.2025.102270","url":null,"abstract":"<div><div>Given the vulnerability of hematopoietic cell transplant (HCT) patients to influenza infection and its complications, annual vaccination is recommended. However, vaccination was known to be less effective in these patients. Multiple studies have assessed various effects in HCT recipients after receiving different vaccine doses. However, the results have been inconclusive. This meta-analysis aims to provide a comprehensive analysis of the effectiveness and safety of HCT recipients when they receive a higher and standard dose of influenza vaccines. This study used PRISMA guidelines on several databases until Oct 25, 2024. We used ROB 2.0 and Review Manager 5.4 Software for further analysis. We included four low-risk of bias studies, and we conducted further analysis. The efficacy of HAI titer <span><math><mo>≥</mo></math></span> 1:40, &gt;4-fold, and confirmed influenza positives was comparable in both groups, with insignificant results in each follow-up group. However, the adverse effect was found significantly higher in the high-dose group, specifically the local adverse effect (<em>p</em> &lt; 0.0001). High-dose influenza vaccines showed higher adverse events and more confirmed influenza cases than standard-dose, suggesting standard-dose may be preferable post-HCT. These findings underscore the need for further research, particularly in diverse populations and vulnerable groups.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102270"},"PeriodicalIF":1.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144749572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamics of monocytic myeloid-derived suppressor cell recovery and interleukin-10 production on graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation","authors":"Arsa Thammahong ,&nbsp;Kitsada Wudhikarn ,&nbsp;Ponlapat Rojnuckarin ,&nbsp;Patsita Kansuwan ,&nbsp;Udomsak Bunworasate ,&nbsp;Chantiya Chanswangphuwana","doi":"10.1016/j.trim.2025.102263","DOIUrl":"10.1016/j.trim.2025.102263","url":null,"abstract":"<div><h3>Background</h3><div>Myeloid-derived suppressor cells (MDSCs) suppress immune responses. We hypothesized that MDSCs and their related cytokines/chemokines after receiving allogeneic hematopoietic cell transplantation (allo-HCT) impact graft-versus-host disease (GVHD) and infectious complications.</div></div><div><h3>Methods</h3><div>This study investigated the dynamics of MDSCs recovery using flow cytometry. Cytokines/chemokines were measured by the Luminex assay and correlated with clinical outcomes.</div></div><div><h3>Results</h3><div>Forty-nine patients who underwent allo-HCT at King Chulalongkorn Memorial Hospital from 2022 to 2023 were enrolled. The median age was 42 years. Most cases (81.6 %) were acute leukemia. Peripheral blood stem cells were collected from human leukocyte antigen-matched related/unrelated donors (85.7 %) or haploidentical donors (14.3 %). Forty-six patients (93.9 %) received myeloablative conditioning regimens. GVHD prophylaxis regimens were calcineurin inhibitor plus methotrexate (67.3 %) and post-transplantation cyclophosphamide (32.7 %). Acute GVHD occurred in 9 (18.4 %) patients with a median onset of 35 days. The percentage of monocytic MDSC (M-MDSC), interleukin-10 (IL-10) and CXCL2 levels on day+28 of acute GVHD patients were all significantly lower than non-GVHD patients (0.26 % vs. 0.55 %, <em>p</em> = 0.048, 15.45 pg/ml vs. 23.53 pg/ml, <em>p</em> = 0.041, and 201.44 pg/ml vs. 428.42 pg/ml, <em>p</em> = 0.029, respectively). Cytomegalovirus (CMV) reactivation was detected in 69.4 % of patients with a median onset of 39 days. CMV reactivation was related to higher M-MDSC percentage on day+14 and IL-10 on day+28 compared with no reactivation (0.76 % vs. 0.22 %, <em>p</em> = 0.047 and 24.35 pg/ml vs. 16.42 pg/ml, <em>p</em> = 0.003, respectively).</div></div><div><h3>Conclusion</h3><div>Delayed M-MDSC reconstitution and low IL-10 were associated with acute GVHD, while high numbers of M-MDSCs and higher IL-10 levels increased the risk of CMV reactivation.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102263"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recombinant human thrombopoietin reduces the risk of acute graft-versus-host-disease and its mechanism","authors":"Hairong Fei ,&nbsp;Xiaodan Liu ,&nbsp;Xiaolin Ma ,&nbsp;Feng Hou ,&nbsp;Peng Jiang ,&nbsp;Lingjie Sun ,&nbsp;Shanshan Liu ,&nbsp;Tianlan Li ,&nbsp;Chunting Zhao","doi":"10.1016/j.trim.2025.102246","DOIUrl":"10.1016/j.trim.2025.102246","url":null,"abstract":"<div><h3>Objective</h3><div>Acute graft-versus-host disease (aGVHD) is a serious complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study aimed to evaluate the effect of recombinant human thrombopoietin (rhTPO) on aGVHD using retrospective clinical data and a xenogeneic GVHD mouse model.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 162 patients who underwent allo-HSCT between 2016 and 2018, comparing outcomes between those treated with rhTPO and those who were not. Additionally, a murine GVHD model was established using irradiated Balb/c mice that received allogeneic PBMCs. Mice were treated with different doses of rhTPO to assess organ pathology, immune cell subsets, and cytokine expression. PBMCs from humans were also treated with rhTPO to assess proliferation and differentiation in vitro. Results were presented as odds ratios (OR) with 95 % confidence intervals (CI), and statistical significance was set at <em>P</em> &lt; 0.05. <em>P</em> &gt; 0.05 was considered statistically significant. All experiments were repeated for 3 times.</div></div><div><h3>Results</h3><div>Clinical analysis showed that rhTPO use and older patient age were independently associated with a lower incidence of aGVHD (<em>P</em> = 0.007 and <em>P</em> = 0.014, respectively). In the xenogeneic mouse model, rhTPO mitigated tissue pathology and modulated immune cell subsets. In vitro, rhTPO regulated PBMC proliferation and enhanced lymphocyte differentiation.</div></div><div><h3>Conclusions</h3><div>rhTPO may reduce the risk of aGVHD by modulating immune responses and protecting tissues, supporting its potential role as an adjunct therapy in allo-HSCT.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102246"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of causal relationship between transplant rejection and immune cells: A two-sample Mendelian randomization study","authors":"Fei Xue ,&nbsp;Xuanpeng Wu ,&nbsp;Ming Ni ,&nbsp;Tao Jiang ,&nbsp;Hao Wang ,&nbsp;Yunfeng Ma ,&nbsp;Qifei Wu","doi":"10.1016/j.trim.2025.102278","DOIUrl":"10.1016/j.trim.2025.102278","url":null,"abstract":"<div><div>Post-transplant rejection is a serious problem for patients undergoing organ transplantation. It is currently believed that immune-related factors are the main causes of transplant rejection, but the roles of many immune cell phenotypes are still unclear.</div><div>We utilized Mendelian randomization analysis to explore the association between 731 immune cell and the risk of transplant rejection.</div><div>We systematically analyzed 731 immune cell phenotypes (including absolute counts, surface markers, and functional states) from peripheral blood of 3657 European individuals. Genetic instruments were selected at a genome-wide significance threshold (<em>p</em> &lt; 1 × 10⁻⁵) to assess bidirectional causal relationships with transplant rejection events from FinnGen biobank (<em>n</em> = 16,380,395 SNPs). Forward MR analysis identified 33 immune phenotypes significantly associated with rejection risk: 19 protective (odds ratio [OR] &lt; 1, <em>p</em> &lt; 0.05) predominantly in B cell subsets, and 14 risk-enhancing phenotypes (OR &gt; 1). Reverse MR revealed that rejection events causally altered 34 immune phenotypes, upregulated 18 effector phenotypes and downregulated 16 regulatory phenotypes. Sensitivity analyses confirmed robustness against pleiotropy (MR-Egger intercept <em>p</em> &gt; 0.05, MR-PRESSO global test <em>p</em> &gt; 0.01 and heterogeneity test p &gt; 0.05). These findings highlight the dynamic interplay between B cell plasticity and Treg depletion in transplant outcomes, suggesting novel therapeutic targets for rejection prevention.</div><div>Our research confirms the close relationship between transplant rejection and immune cells, especially that certain B cell subsets are causally linked to a lower risk of transplant rejection, providing new targets and insights for future clinical treatments.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102278"},"PeriodicalIF":1.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144904580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy of Naringenin and Sinomenine in facilitating the differentiation of mouse hematopoietic stem cells into immature dendritic cells to promote transplantation immunological regulation","authors":"Cuixiang Xu ,&nbsp;Xiangrong Zhao ,&nbsp;Zejiaxin Niu ,&nbsp;Ying Wang ,&nbsp;Xinlu Jiang ,&nbsp;Jiaxin Tian ,&nbsp;Yangmeng Feng ,&nbsp;Xiaoyan Huang ,&nbsp;Puxun Tian","doi":"10.1016/j.trim.2025.102260","DOIUrl":"10.1016/j.trim.2025.102260","url":null,"abstract":"<div><h3>Objective</h3><div>Immature dendritic cells (imDC) are crucial in facilitating transplant immunological regulation. However, imDC is readily amenable to maturation. Sinomenine (Sin) naringin (Nar) are traditional Chinese medicine with immunoregulation and anti-inflammatory activities. We investigated the effect of Sin and Nar on the generation of immature dendritic cells (imDC) and their ability to prolong the survival of skin allografts in mice.</div></div><div><h3>Methods</h3><div>Hematopoietic stem cells (HSC) obtained from bone marrow prompted to develop into immature dendritic cells (imDC) through treatment with Sin (Sin-HSC-imDC) or Nar (Nar-HSC-imDC). The cell counting kit-8 (CCK-8) assay was employed to assess the differentiating efficacy of Sin-HSC-imDC and Nar-HSC-imDC. DC surface markers and apoptosis following lipopolysaccharide (LPS) treatment were assessed by flow cytometry, while apoptosis-related genes using qPCR. The impact of Sin-HSC-imDC and Nar-HSC-imDC on the generation of regulatory T cells (Tregs) was evaluated by mixed lymphocyte reactions. Cytokine expression was quantified using enzyme-linked immunoassays (ELISA). The immunomodulatory effects of Sin-HSC-imDC and Nar-HSC-imDC were evaluated by performing skin transplantation experiments in Balb/c mice recipients models. Kaplan-Meier technique was employed for graft survival outcomes.</div></div><div><h3>Results</h3><div>In vitro assays, in comparison to Sin-HSC-imDC, Nar-HSC-imDC had higher CD11c expression and lower CD80 as markers for imDCs (<em>P</em> <em>&lt;</em> <em>0.05</em>) and promoted the generation of Tregs proliferation (<em>P</em> <em>&lt;</em> <em>0.05</em>). Interleukin 2 (IL-2) and interferon gamma (IFN-γ) levels diminished in Nar-HSC-imDC groups (<em>P</em> <em>&lt;</em> <em>0.05</em>), but interleukin 10 (IL-10) and transforming growth factor-beta (TGF-β) levels elevated (<em>P</em> <em>&lt;</em> <em>0.05</em>). And the apoptosis rate of Nar-HSC-DC increased significantly after LPS treatment (<em>P</em> <em>&lt;</em> <em>0.05</em>). In vivo assays, when Balb/c mice received Nar-HSC-imDC or Sin-HSC-imDC via the tail vein seven days before skin transplantation, mice from the Nar-HSC-imDC group had increased CD4⁺CD25⁺CD127⁻ Tregs proliferation in the spleen (<em>P</em> <em>&lt;</em> <em>0.05</em>), which prolonged skin graft survival, and that was better than in Sin-HSC-imDC group.</div></div><div><h3>Conclusion</h3><div>Nar was exposured more efficient in inducing differentiation of HSC into imDC than Sin. Nar-HSC-imDC had stronger ability in inducing specific immune hypo-responsiveness than Sin-HSC-imDC.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102260"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144262741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Donor lymphocyte infusion-based therapy for relapsed adult T-cell leukemia/lymphoma after HLA-haploidentical hematopoietic stem cell transplantation","authors":"Shinichi Katsuoka ,&nbsp;Hidehiro Itonaga ,&nbsp;Miki Hashimoto ,&nbsp;Hikaru Sakamoto ,&nbsp;Takafumi Furumoto ,&nbsp;Yuichi Yamada ,&nbsp;Takeharu Kato ,&nbsp;Makiko Horai ,&nbsp;Shinya Sato ,&nbsp;Koji Ando ,&nbsp;Kazuhiro Nagai ,&nbsp;Nariyoshi Matsumoto ,&nbsp;Daisuke Sasaki ,&nbsp;Hiroo Hasegawa ,&nbsp;Yoshitaka Imaizumi ,&nbsp;Katsunori Yanagihara ,&nbsp;Yasushi Miyazaki","doi":"10.1016/j.trim.2025.102262","DOIUrl":"10.1016/j.trim.2025.102262","url":null,"abstract":"<div><div>Donor lymphocyte infusion (DLI) combined with chemotherapy is an effective therapy for relapsed adult T-cell leukemia/lymphoma (ATL) after allogeneic hematopoietic stem cell transplantation from a human leukocyte antigen (HLA)-matched related donor or matched unrelated donor. The 1-year incidence of ATL relapse is 28 % after HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide. However, the efficacy of DLI for relapsed ATL after haplo-HSCT remains unclear. Here, we present the case of a 61-year-old woman diagnosed with ATL who underwent haplo-HSCT from an HLA-haploidentical relative donor. On day +164 after transplantation, the patient experienced ATL relapse. Tacrolimus was tapered and discontinued on day +216; however, ATL progressed. Since the patient did not develop graft-versus-host disease (GVHD) after the discontinuation of tacrolimus, DLI following chemotherapy was performed for relapsed ATL. The patient achieved complete remission without severe GVHD after the 6th DLI treatment. This remission has been sustained for over 15 months with 13 DLI treatments. These results suggest the potential of DLI combined with chemotherapy as a treatment option for patients with relapsed ATL after haplo-HSCT.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102262"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144366002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testing controls demonstrates a high prevalence of non-HLA antibody positivity using pre-defined cutoff threshold in a bead-based assay using healthy control population","authors":"A. Agrawal ,&nbsp;M. Zuccarelli ,&nbsp;L.L. Wakefield ,&nbsp;C.A. Schinstock ,&nbsp;M.J. Gandhi ,&nbsp;A.J. Bentall","doi":"10.1016/j.trim.2025.102265","DOIUrl":"10.1016/j.trim.2025.102265","url":null,"abstract":"<div><h3>Background</h3><div>Measuring non-HLA antibodies is a potentially important tool in assessing allograft dysfunction and needs to be correlated with clinical outcomes. Thus, determining the antibody distribution in healthy populations is important before correlating with clinical events. Using male blood donors, we selected a low immunological risk control cohort.</div></div><div><h3>Methods</h3><div>We analyzed samples from 92 male, non-transfused blood donors (donors) to assess the detection of antibodies in a normal population cohort using a non-HLA 33 antigen multiplex commercial assay.</div></div><div><h3>Results</h3><div>At manufacturer's suggested cutoff threshold (COT) of 75 % percentile, no donors had negative results and at 95 % percentile only three donors were negative across all 33 antigens. At each of the manufacturer's COT, the median (IQR) number positive antibody bead tests per donor was 13 (10–17), 11 (8–13) and 7 (5–10) at 75th, 85th and 95th percentile COT, respectively. There was poor correlation between manufacturer's COT and locally generated COT (range <em>r</em> = 0.520 to 0.595). The percentage of donors who had three or more positive antibody bead tests was: 98.9 % at 75th COT; 95.7 % at 85th COT and 93.5 % at 95th COT.</div></div><div><h3>Conclusions</h3><div>Considering the high proportion of positive results in a low immunological risk cohort, application of non-HLA antibody measurement in a diseased cohort is not optimal, and difficult to correlate with clinical events. Further studies to determine normal detection rates are needed for assay COT and clinical application in diseases.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102265"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144665922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Syngeneic hematopoietic stem cell transplantation from an identical twin sister in an AML patient: “A case report highlighting accelerated engraftment and reduced transfusion requirements”","authors":"Ehsan Yazdandoust ,&nbsp;Abbas Hajifathali ,&nbsp;Zeinab Kaboli ,&nbsp;Sedigheh Amini-Kafiabad","doi":"10.1016/j.trim.2025.102267","DOIUrl":"10.1016/j.trim.2025.102267","url":null,"abstract":"<div><h3>Background and objective</h3><div>Hematopoietic stem cell transplantation (HSCT) is among the most effective immunotherapeutic strategies for treating hematologic malignancies in both pediatric and adult patients. Its global use has been steadily increasing. Patients undergoing HSCT commonly require transfusion support with blood products until engraftment is achieved, and transfusion requirements can significantly affect post-transplant outcomes. Despite advancements that have improved survival rates, transplant-related mortality (TRM) continues to be a major obstacle to optimal outcomes.</div></div><div><h3>Case presentation</h3><div>We present the case of a 46-year-old woman diagnosed with acute myeloid leukemia (AML) harboring an FLT3-ITD mutation, who underwent allogeneic HSCT. The donor was her identical twin sister, with full HLA compatibility (a 10/10 match) and an identical ABO blood group (O positive). Notably, the patient exhibited rapid neutrophil and platelet engraftment by day +9, which is earlier than typically observed in transplants from fully matched related or unrelated donors. Furthermore, the patient did not require any red blood cell or platelet transfusions during the transplantation period and developed no signs of acute or chronic graft-versus-host disease (GVHD). She has remained disease-free with no evidence of relapse for over three years post-transplant.</div></div><div><h3>Conclusion</h3><div>HSCT from an identical twin donor may provide favorable clinical outcomes, including accelerated engraftment and reduced transfusion needs during the transplantation process.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102267"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144656988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early post-lung transplant cell-free DNA levels are associated with baseline lung allograft function","authors":"Andrea Zajacova ,&nbsp;Majd Alkhouri ,&nbsp;Goncalo Ferrao ,&nbsp;Miray Guney ,&nbsp;David Rezac ,&nbsp;Kristyna Vyskocilova ,&nbsp;Tereza Kotowski ,&nbsp;Alzbeta Dutkova ,&nbsp;Eliska Dvorackova ,&nbsp;Robert Lischke ,&nbsp;Libor Fila ,&nbsp;David J. Ross ,&nbsp;Bart Vanaudenaerde ,&nbsp;Jan Havlin","doi":"10.1016/j.trim.2025.102245","DOIUrl":"10.1016/j.trim.2025.102245","url":null,"abstract":"<div><h3>Background</h3><div>Baseline lung allograft dysfunction (BLAD) is defined as the failure to achieve normal pulmonary function—specifically, forced expiratory volume in 1 s (FEV₁) and forced vital capacity (FVC) values of ≥80 %—within the first year after lung transplantation. It is hypothesised that early subclinical injury, reflected by elevated donor-derived cell-free DNA (dd-cfDNA), both in absolute concentration and percentage (dd-cfDNA%), as well as total cell-free DNA (cfDNA), may be predictive of subsequent BLAD development.</div></div><div><h3>Methods</h3><div>We included patients who underwent bilateral lung transplantation between May 2021 and September 2023. Blood samples collected between 3 and 9 months post-transplantation were analysed for dd-cfDNA%, dd-cfDNA concentration (copies/mL), and estimated total cfDNA (copies/mL). BLAD was defined by failure to achieve both FEV₁ and FVC ≥80 % of predicted values within the first year.</div></div><div><h3>Results</h3><div>A total of 158 samples from 37 patients were analysed. Ten patients (27 %) met the BLAD criteria. Those with BLAD had significantly higher dd-cfDNA levels (median: 39 cp/mL) compared to non-BLAD patients (26 cp/mL; <em>p</em> = 0.01). Similarly, total cfDNA levels were significantly elevated in the BLAD group (22,809 cp/mL vs. 13,840 cp/mL; <em>p</em> = 0.002). However, dd-cfDNA% did not differ significantly (0.23 % vs. 0.15 %; <em>p</em> = 0.2).</div></div><div><h3>Conclusion</h3><div>Elevated absolute dd-cfDNA and total cfDNA levels in the early post-transplant period were associated with BLAD, suggesting that cfDNA may serve as a potential predictive biomarker. These findings support the potential of cfDNA-based biomarkers to enhance early detection of graft dysfunction, warranting validation in larger cohorts.</div></div>","PeriodicalId":23304,"journal":{"name":"Transplant immunology","volume":"92 ","pages":"Article 102245"},"PeriodicalIF":1.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}